Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

— CSCR  

Official title:

Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05847049
• Other study ID #: N-20-2023
• Status: Completed
• Start date: February 28, 2023
• Est. completion date: April 6, 2023

Study information

• Verified date: April 2023
• Source: Dar El Oyoun Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Description:

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.

Investigators collected and recorded the following data:

• Age

• Gender

• Systemic hypertension (present or not)

• Smoking (Yes / No)

• Best corrected visual acuity (BCVA) (baseline, final)

• Central macular thickness (CMT) (baseline, final)

• Serous detachment Height (SDH) (baseline, final)

• Duration of Follow-up ( in months)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 6, 2023
• Est. primary completion date: March 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 60 Years

Eligibility

Inclusion Criteria:

• CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion Criteria:

• • CSCR treated by other modalities

• CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Intervention

Other:
• Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Locations

Country	Name	City	State
Egypt	Kasr alainy faculty of medicine	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Dar El Oyoun Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in central macular thickness (CMT ) in microns	reduction in CMT after therapy	(baseline, 6 months)
Primary	Change in serous detachment height (SDH) in microns	reduction in SDH after therapy	(baseline, 6 months)
Secondary	Change in BCVA	number of lines of improvement in BCVA after therapy	(baseline, 6 months)
Secondary	Duration of Follow-up ( in months)	Duration of Follow-up ( in months)	(baseline, 6 months)
Secondary	Complications (Eplerenone, Aflibercept, and nepafenac)	present or absent	(baseline, 6 months)